



Polybrominated diphenyl ethers (flame retardants) in mother-infant pairs in the Southeastern U.S.

Paul Terry^a, Craig V. Towers^b, Liang-Ying Liu^c, Angela A. Peverly^d, Jiangang Chen^e and Amina Salamova^f

^aDepartments of Medicine, University of Tennessee Medical Center, Knoxville, TN, USA; ^bObstetrics and Gynecology, University of Tennessee Medical Center, Knoxville, TN, USA; ^cSchool of Environment and Guangzhou Key Laboratory of Environmental Exposure and Health, Jinan University, Guangzhou, China; ^dScience and Mathematics Department, Eureka College, Eureka, IL, USA; ^eDepartment of Public Health, University of Tennessee, Knoxville, TN, USA; ^fSchool of Public and Environmental Affairs, Indiana University, Bloomington, IN, USA

ABSTRACT

Polybrominated diphenyl ethers (PBDEs) are commonly used flame retardants in foams, building material, electronics, and textiles. These chemicals leach into the environment, where they persist, and are found today in virtually every population worldwide. Several studies in recent years have detected the presence of PBDEs in maternal and infant samples. However, few of these studies were conducted in the U.S., and few examined paired or matched mother blood-cord blood samples. We analyzed serum from 10 mother-infant pairs for the presence of PBDEs in a patient population in the Southeastern U.S. Out of 35 measured PBDE congeners, five (BDE-28, -47, -99, -100, and -153) were present, with detection frequencies of 65–100%. The total PBDE concentrations in maternal and infant sera were highly correlated ($r^2 = 0.710$, $p = 0.0043$). The levels of BDE-47, -99, and -100 and of total PBDEs were higher in the infant cord sera when compared with those in maternal sera ($p < 0.017$), suggesting that fetuses and neonates might have higher circulating concentrations of these potentially neurotoxic and endocrine disrupting chemicals compared with their mothers. The primary focus henceforward should be whether there are any deleterious effects from exposure to these chemicals on human health.

ARTICLE HISTORY

Received 26 September 2016
Accepted 4 May 2017

KEYWORDS

PBDEs; fetal exposure;
maternal exposure

Introduction

Polybrominated diphenyl ethers (PBDEs) are commonly used flame retardants in foams, building materials, electronics, and textiles. These compounds are classified by the number of bromine atoms in the molecule, ranging from 1 (mono-) to 10 (deca-); overall there are 209 different congeners (Alaee et al. 2003). These chemicals are lipophilic, have a similar structure to thyroid hormones, are highly resistant to degradation, and are common contaminants of dust, various foods, such as fish, dairy products, and meats, and air, water, soil, and sediments (Darnerud et al. 2001; Frederiksen et al. 2009; Domingo, 2012). The widespread use of PBDEs in the past few decades (Sjodin et al. 2004) and their persistence in the environment (Sjodin et al. 2001; de Wit, 2002; Hites, 2004) and human tissues

(Covaci et al. 2008) explain the presence observed in virtually every human population (Darnerud et al. 2001; Hites, 2004; Bi et al. 2006; Jaraczewska et al. 2006; Kawashiro et al. 2008; Meijer et al. 2008; Antignac et al. 2009; Kim et al. 2009; Vizcaino et al. 2011; Kim et al. 2012; Arbuckle et al. 2013; Chen et al. 2013).

PBDEs have been detected in fetal (Schecter et al. 2007), child and adult (Pacyniak et al. 2010) organ tissues, umbilical cord blood, human adipose tissue (Covaci et al. 2002; Petreas et al. 2011), and human breast milk (Carrizo et al. 2007). Several studies have linked these compounds to hormone disruption, especially thyroid hormones and estrogen (Meerts et al. 2001; Vuong et al. 2015), neurodevelopment toxicity (Eriksson & Fredriksson 1996; Viberg et al. 2002; Kuriyama et al. 2005; Costa & Giordano 2007; Dingemans et al. 2008; Roze et al. 2009; Herbstman et al. 2010), and lower birth weight and length (Chao et al. 2007). Because of these health concerns, PBDE commercial products are no longer manufactured in the United States, and have been banned by the European Union and Canada (Carrizo et al. 2007). Nonetheless, the compounds persist in the environment and in human tissues analyzed as recently as 2015, causing on-going exposure in humans.

Several studies have been performed in the last 14 years analyzing the presence of PBDEs in mothers and infants. These studies are important, especially if infant and childhood neurodevelopment is a concern. However, few of these studies were conducted in the U.S., and few examined paired or matched mother blood-cord blood samples. Here, we present the results of a recent study of mother-infant pairs in the Southeastern U.S., which analyzed maternal serum and umbilical cord blood from mother-infant pairs for the presence of PBDEs. We also provide a brief review of the more recent data on transplacental passage of PBDEs.

Materials and methods

All pregnant patients that entered labor and delivery at University of Tennessee Medical Center, Knoxville, were eligible. We enrolled 10 pregnant patients resulting in an analysis of 20 samples (10 mothers and 10 infants). Eligible patients were approached to participate in the study once they were admitted in active labor. If they agreed, an approved informed consent form was signed. The study was reviewed and approved by the institutional review board of the UT Graduate School of Medicine.

Once consented, an additional tube of blood was collected at the time the pregnant mother's admission blood work was obtained. At delivery, an additional tube of cord blood was also obtained, creating matched samples of mother and newborn. Samples were immediately processed and sera were frozen until analyzed for the presence of 35 common PBDE congeners (7, 10, 15, 17, 28, 30, 47, 49, 66, 85, 99, 100, 119, 126, 138–140, 153, 154, 156, 169, 180, 183, 184, 191, 196, 197, 201, and 203–209).

Information collected on the participating pregnant mothers included age, ethnicity, body mass index (BMI) at delivery, gestational age, type of delivery, and any major medical disorders (such as hypertension or diabetes). Neonatal data collection included birth weight, gender, Apgar score, and any neonatal complications.

Sample preparation and analysis

Sera samples (approximately 2–3 mL) were thawed overnight, weighed, transferred to a 50 mL screw-top tube, and spiked with known amount of surrogate recovery standards (BDE-77, BDE-166, and $^{13}\text{C}_{12}$ -BDE-209). Each sample was denatured consecutively with 2 mL of hydrochloric acid (6 M) and 2 mL of 2-propanol. Samples were extracted with 10 mL of *n*-hexane : methyl *tert*-butyl ether (MTBE) (1:1 v/v) for three times. Extracts were combined and a small aliquot was taken for gravimetric lipid measurement. The remaining extract was rotary evaporated to approximately 1 mL with one solvent change of 25 mL of *n*-hexane and then fractionated on a 6 g of 2.5 % (by weight) water deactivated Florisil column. The column was eluted with 35 mL of *n*-hexane, then 35 mL of *n*-hexane : dichloromethane (1:1 vol) and the two fractions collected separately. Both fractions were rotary evaporated to approximately 1 mL and the second fraction was further solvent changed to *n*-hexane once. Each

fraction was transferred to a 4 mL amber glass vial and nitrogen blown down to 1 mL, spiked with BDE-118, BDE-181, and BB-209 as internal standards and further blown down to 0.1 mL for the analysis of PBDEs. PBDEs were eluted in both fractions.

Instrumental analysis

The analyses of 35 PBDE congeners (7, 10, 15, 17, 28, 30, 47, 49, 66, 85, 99, 100, 119, 126, 138–140, 153, 154, 156, 169, 180, 183, 184, 191, 196, 197, 201, and 203–209) were done on an Agilent 7890 series gas chromatograph (GC) coupled to an Agilent 5975C mass spectrometer (MS) operating in the electron capture negative ionization (ECNI) mode. Chromatographic separation was accomplished with an Rtx-1614 (15 m, 250 μ m i.d., 0.1 μ m film thickness) fused silica capillary GC column (Restek Corporation, Bellefonte, CA). High purity helium (99.999 %; Liquid Carbonic, Chicago) was used as the carrier gas and high purity methane (99.97 %, Praxair) was used as the reagent gas. Instrument detection limits ranged from 0.03 to 0.09 ng. Details on the instrumental analysis procedures have been previously reported (Ma et al. 2013). All samples were quantitated using the internal standard method.

Quality assurance and quality control

Samples were obtained and processed in 2013, following standard operating procedures and quality assurance and quality control measures. A procedural blank (total of three blanks) was run with every batch of samples. Average blank concentrations were 0.040, 0.025, 0.01, and 0.025 ng for BDE-47, -99, -100, and -153, respectively. BDE-28 was not detected in blanks. Concentrations below the average blank levels were treated as non-detects and replaced with empty cells in the data spreadsheet. The surrogate recoveries (average \pm stt. error) were 110 ± 11 , 75 ± 4 , and 51 ± 5 % for BDE-77, BDE-166, and $^{13}\text{C}_{12}$ -BDE-209, respectively. None of the concentrations were corrected for surrogate recoveries. All concentrations were adjusted for the lipid content of the sample. Lipid content (average \pm st. error) for maternal sera was 0.99 ± 0.08 g (range of 0.49–1.5 g), while for cord sera it was 0.24 ± 0.06 g (range of 0.05–0.66 g).

Results

A total of 10 mother–infant pairs were recruited with 9 Caucasian and 1 Asian. The mean maternal age was 29.2 years with a range of 21–39. The mean BMI at delivery was 33.8 with a range of 24–51. There were four patients with a BMI of <30 ; 4 with a BMI of 30 to <40 ; and 2 with a BMI of ≥ 40 . There was no clear correlation between PBDE level and BMI; concentrations are expressed on a lipid weight basis.

Out of 35 measured PBDE congeners, five were present with the detection frequencies of 65–100 % (Table 1) and only these congeners (BDE-28, -47, -99, -100, and -153) are discussed below. Of the five congeners, BDE-47 was the most abundant congener comprising 23–74 % of total PBDE concentrations, followed by BDE-99 (at 12–43 %). Both maternal and infant sera (from cord blood) had similar congener profiles, with the exception of BDE-99 which was relatively enriched in infant sera at 36 ± 8 % of total PBDE concentrations vs. 20 ± 2 % in maternal sera. The concentrations of total PBDEs in maternal sera ranged from 10 to 62 ng/g lipid weight (lw), whereas these concentrations in infant sera ranged from 17 to 120 ng/g lw (Figure 1). The total PBDE concentrations in maternal and infant sera were highly correlated ($r^2 = 0.710$, $p = 0.0043$ with the sample #2 excluded as an outlier). The levels of BDE-47, -99, -100 and of total PBDEs were higher in the infant cord sera when compared with the maternal sera concentrations ($p = 0.017$). In every mother–infant pair, the infant total PBDE concentration was higher than that in the maternal sample. We observed the same pattern when we examined individual PBDEs in our samples (Table 1). The average ratio of cord to maternal (CM) total PBDE concentrations was 2.1 ± 0.32 , similar to the CM ratio for BDE-28, -47, and -100 at 2.5 ± 0.87 , 2.2 ± 0.40 , and 2.6 ± 0.64 , respectively. This ratio was higher for BDE-99 concentrations at 3.7 ± 0.62 , and lower for BDE-153 at 1.9 ± 0.78 .

Table 1. Concentrations of polybrominated diphenylethers (PBDEs) in ten paired maternal serum and fetal cord blood samples (ng / g lipid weight).

Mother	BDE-28	BDE-47	BDE-99	BDE-100	BDE-153	Total PBDE*	Child	BDE-28	BDE-47	BDE-99	BDE-100	BDE-153	Total PBDE
1	2.61	9.41	5.23	2.61	2.61	22.5	1	2.93	41.0	11.7	n.d	n.d	55.6
2	0.710	5.68	2.13	1.42	n.d.	9.94	2	5.69	39.8	34.1	22.8	n.d	102
3	0.429	8.58	3.86	2.15	1.72	16.7	3	3.17	28.5	28.5	12.7	n.d	72.8
4	0.931	9.62	3.10	1.86	3.73	19.2	4	1.25	14.9	8.72	6.23	n.d	31.1
5	n.d.	2.62	3.49	1.31	3.93	11.4	5	n.d	n.d	19.2	n.d	n.d	19.2
6	0.338	8.44	4.39	1.69	7.09	21.9	6	n.d	11.3	18.8	3.76	9.39	43.2
7	0.857	9.85	3.43	3.85	10.3	28.3	7	1.42	15.6	14.2	2.83	7.08	41.1
8	5.30	26.5	7.94	8.83	13.2	61.8	8	4.99	54.8	19.9	19.9	19.9	120
9	1.11	14.4	4.44	3.33	2.22	25.5	9	3.74	31.8	11.2	9.34	9.34	65.4
10	0.504	8.56	3.02	2.52	2.01	16.6	10	0.787	8.65	4.72	3.15	n.d	17.3
Median	0.857	9.00	3.68	2.33	3.73	20.6	Median	3.05	28.49	16.47	7.78	9.37	49.4
Mean	1.42 ± 0.535	10.4 ± 2.03	4.10 ± 0.507	2.96 ± 0.701	5.20 ± 1.37	23.4 ± 4.64	Mean	3.00 ± 0.630	27.4 ± 5.29	17.1 ± 2.85	10.1 ± 2.74	11.4 ± 2.89	56.8 ± 10.8
Range	(n.d. - 5.30)	(n.d. - 26.5)	(n.d. - 7.94)	(-n.d. - 8.83)	(-n.d. - 13.2)	(9.94 - 61.8)	Range	(0.787 - 5.69)	(8.65 - 54.8)	(4.72 - 34.1)	(2.82 - 22.8)	(7.08 - 19.9)	(17.3 - 120)

Note: (N.D. = not detected).

*Total PBDE concentrations are the sum of the concentrations of the five individual PBDE congeners included in this table.




Figure 1. Total PBDE concentrations (the sum of BDE-28, 47, 99, 100, and 153, ng/g lipid weight) in matched maternal and fetal cord blood samples.

We provide a summary of the reports on this subject extending back 14 years (Table 2). As demonstrated, every study has found some PBDEs in both maternal samples and infant cord blood.

Comment

The results of our study are consistent with those of previous studies showing that PBDEs are found in maternal blood, cross the placenta and enter fetal circulation. Our results show that the levels of PBDEs in cord blood samples are higher than those in maternal samples collected at delivery. These increased levels of PBDEs in cord sera were evident in each maternal–infant sera pair, suggesting that fetuses and neonates might have higher circulating concentrations of these potentially neurotoxic and endocrine disrupting chemicals compared with their mothers.

The elevated PBDE concentrations found in infant sera in this study are consistent with the recent studies on PBDE distribution between infant and maternal blood (Chen et al. 2013; Choi et al. 2014). The congener profiles are similar between the maternal and infant samples, with BDE-47 accounting for about half of total PBDE concentrations. BDE-99 contribution to total PBDE concentrations was higher in cord blood than in maternal blood; and BDE-153 contribution was higher in maternal blood than that in cord blood. The latter observations were reported in several previous studies (Mazdai et al. 2003; Chen et al. 2013) and perhaps may be due to differences in the congeners ability to pass through the placenta.

Overall, given that the PBDE concentrations measured in maternal and infant sera were highly correlated, and the congener profiles were similar between maternal and fetal samples, it may be worth considering when planning an investigation to what extent measuring both may be redundant.

Despite the small sample size, our study is the first to include samples from mother–infant pairs living in the Southeastern United States. There are only three other such studies from North America, two from the Mid-western United States (Mazdai et al. 2003; Chen et al. 2013) and one from Canada (Foster et al. 2011). Our results are consistent with those reported in the U.S. samples, but lower than those found in the mothers and neonates in Canada (median at 50–100 ng/g lw, respectively). In all three studies, BDE-47 was the most abundant congener, similar to our findings. This might be explained by the fact that BDE-47 is the major component of the Penta-BDE commercial product that was widely used in North America until 2004. The latter might also explain generally lower PBDE concentration measured in European cohorts.

Table 2. Summary of the literature on PBDE concentrations in maternal and fetal cord blood (ng/g lipid weight).

Study	Location	Samples Tested	PBDEs Measured	Total PBDEs Median (range)
Current study	USA	10 maternal 10 cord blood (paired)	28, 47, 99, 100, 153	M ^a : 20.6 (9.94–61.8) C ^b : 49.4 (17.3–120)
(Chen et al. 2014)	South China	30 cord blood	17, 28, 47, 99, 138, 153, 154, 183, 197	9.73 (1.02–71.3)
(Choi et al. 2014)	South Korea	198 maternal serum 118 cord blood (paired)	28, 47, 49, 66, 71, 77, 85, 99, 100, 119, 126, 153, 154	M: 1.83 (0.93–3.81) C: 1.93 (0.55–3.56)
(Li et al. 2013)	China	29 maternal serum 29 cord blood (paired)	17, 28, 47, 49, 66, 206, 207, 208, 209	M: 29.3 C: 41.1
(Chen et al. 2013)	USA	20 maternal serum 20 cord blood (paired)	28, 47, 99, 100, 153, 154, 209	M: 28.5 (7.46–176) C: 41.5 (17.9–171)
(Kim et al. 2012)	South Korea	21 maternal serum 21 cord blood (paired)	28, 47, 99, 100, 153, 154, 183	M: 7.81 (1.8–17.7) C: 12.0 (2.28–30.9)
(Kim et al. 2011)	South Korea	90 cord blood	28, 47, 99, 100, 153, 154, 183	16.43 ^c (2.78–94.64)
(Jakobsson et al. 2012)	Sweden	10 maternal serum 10 cord blood (paired)	28,47,99,153,154,197,209	M: 11.3 (3.30–32.4) C: 4.7 (1.2–26)
(Arbuckle et al. 2013)	Canada	Cord blood samples ^d	17, 28, 47, 66, 99, 100, 153, 154, 183	nd ^e
(Foster et al. 2011)	Canada	97 maternal serum 97 cord blood (paired)	17, 28, 47, 66, 99, 100, 153, 154, 183	M: 54.7 (6.84–1103) C: 113 (51.1–1450)
(Vizcaino et al. 2011)	Spain	174 maternal serum 174 cord blood (paired)	47, 99, 153, 154, 209	M: 9.6 (n.d-140) C: 9.6 (n.d-120)
(Lin et al. 2011)	Taiwan	54 cord blood	15, 28, 47, 99, 100, 153, 154, 183	3.49 (1.65–47.3)
(Wu et al. 2010)	China	153 cord blood	28, 47, 99, 100, 153, 154, 209	M: 13.8 (1.14–505) C: 5.23 (0.29–364)
(Frederiksen et al. 2010)	Denmark	51 maternal serum 40 cord blood	28, 47, 99, 100, 153, 154	M: 1.76 (0.64–51.9) C: 0.958 (0.213–54.5)
(Herbstman et al. 2010)	USA	210 cord blood	47, 85, 99, 100, 153, 154, 183	18.8
(Kang et al. 2010)	South Korea	20 maternal serum 20 cord blood (paired)	28,47,99,100,153,154,197, 203,207,209	M: 7.8 (0.00–270) C: 13 (0.00–480)
(Kim et al. 2009)	South Korea	108 cord blood	28, 47, 99, 100, 153, 154, 183	8.23 (n.d.-29.4)
(Antignac et al. 2009)	France	91 maternal serum 90 cord blood (paired)	28, 47, 85, 99, 100, 118, 153, 154, 155, 183, 190, 196, 197, 201, 202, 203, 206, 207, 208, 209	M: 9.83 (0.474–81.5) C: 13.0(1.03–380)
(Kawashiro et al. 2008)	Japan	16 maternal serum 8 cord blood	15, 28, 47, 49, 66, 85, 99, 100, 153, 154, 197, 207, 209	M: 3.0 (1.8–17) C:0.65 (0.30–6.2)
(Meijer et al. 2008)	Netherlands	12 maternal serum 12 cord blood (paired)	47, 99, 100, 153, 154	3.3 (0.47–33.1)
(Herbstman et al. 2007)	USA	297 cord blood	28, 47, 85, 99, 100, 153, 154, 183	26.6 (n.d-672)
(Gomara et al. 2007)	Spain	113 maternal serum 92 cord blood	17, 28, 47, 66, 85, 99, 100, 153, 154, 183, , 191, 196, 197, 209	M: 12 (5.5–43); 9.7 (4.4–46) C: 17 (6.3–82); 15 (4.3–38)
(Carrizo et al. 2007)	Spain	92 cord blood	17, 28, 47, 99, 100, 183,	6.2 ± 7.2
(Bi et al. 2006)	South China	21 maternal serum 21 cord blood (paired)	28, 47, 99, 100, 153, 154, 183	M: 4.4 (1.6–17) C: 3.9 (1.5–12)
(Weiss et al. 2004)	Sweden	78 maternal and 12 cord blood samples	47, 99, 100, 153, 154	8.18 (0.9–26)
(Guvenius et al. 2003)	Sweden	15 maternal serum 15 cord blood (paired)	17, 28, 47, 66, 85, 99, 100, 153, 154, 183	M: 2.07(0.71–8.39) C: 1.69(0.46–4.28)
(Mazdai et al. 2003)	USA	12 maternal serum 12 cord blood (paired)	47, 99, 100, 153, 154, 183	M: 37 (15–580) C: 39 (14–460)

^aM: maternal^bC: cord^cMean^dSample size was not available^end: not detected^fdata from two different locations.

Experimental animal models have shown deleterious effects, such as developmental neurotoxicity, from pre-natal exposure to PBDEs (Costa & Giordano 2007; Costa et al. 2008). In humans, a few Asian studies have investigated neonatal PBDE levels in relation to stillbirth, low birth weight, and pre-term birth, with some showing increased risks among infants with higher cord blood (Wu et al. 2010) or breast milk (Chao et al. 2007). In a U.S. cohort study, Herbstman and colleagues (Herbstman et al. 2010) found that cord blood PBDE levels were inversely associated with tests of mental and physical development at 12, 48, and 72 months after birth. In a cohort of Dutch children, Roze and colleagues (Roze et al. 2009) found some weaker associations between higher levels of PBDE exposure with health outcomes, but their results overall did not support the U.S. findings. This is not surprising, however, because PBDE exposure levels in the U.S. cohort were several times higher, consistent with the appreciably higher environmental levels in North America compared with Europe and Asia (Foster et al. 2011). Ezkenazi and colleagues investigated the association between *in utero* and child PBDE exposure with neurobehavioral development among participants in a California birth cohort (Eskenazi et al. 2013) finding inverse associations between PBDE levels and IQ, particularly processing speed, verbal comprehension, and perceptual reasoning. PBDE levels were positively associated with hyperactivity.

There is now ample evidence for the placental transfer of PBDEs during pregnancy. However, epidemiologic studies of PBDE exposure and health outcomes in humans remain limited in number and scope (Linares et al. 2015). Future studies should include new or additional analyses of data from studies that are already measuring prenatal PBDE exposure in relation to health endpoints, and new flame retardant chemicals that replace those that have been phased out (Linares et al. 2015). Moreover, the current literature reveals several methodological limitations that may be addressable in future studies. For example, post-natal exposure of infants and children to PBDEs through breastfeeding, food, transdermal absorption, and dust (Guvenius et al. 2003; Carrizo et al. 2007; Herbstman et al. 2010) suggests the need for repeated measures of exposure during follow-up to reduce measurement error. To further improve validity, multivariate models may be used (in sufficiently large studies) to assess and control confounding from such factors as maternal age, pre-pregnant BMI, weight gain during pregnancy, maternal smoking, sex of child, race/ethnicity, rural or city residence, various socioeconomic factors, psychosocial stress, and gestational age (Herbstman et al. 2010; Lin et al. 2011). Future studies should also address possible interactions of PBDEs with PCBs and other chemicals in causing disease (Herbstman et al. 2010), as well as with individual genetic and epigenetic factors (Herbstman et al. 2007).

Conclusion

To our knowledge, this is the first study of PBDE levels in mother–infant pairs in the Southeastern U.S. As we expected, mother–infant PBDE levels were highly correlated, and PBDE levels were consistently higher in the infant of each mother infant pair, suggesting that fetuses and neonates may have higher circulating concentrations of these potentially neurotoxic and endocrine disrupting chemicals compared with their mothers. The primary focus henceforward should be whether there are any deleterious effects from exposure to these chemicals on human health. A definitive answer requires additional long-term follow-up studies of newborns that discern any differences in health based on PBDE levels that might be found at various times during pregnancy, at birth, and over the subsequent years of follow-up.

Disclosure statement

No potential conflict of interest was reported by the authors.

References

- Alaee M, Arias P, Sjödin A, Bergman Å. 2003. An overview of commercially used brominated flame retardants, their applications, their use patterns in different countries/regions and possible modes of release. *Environ Int.* 29:683–689.
- Antignac JP, Cariou R, Zalko D, Berrebi A, Cravedi JP, Maume D, Marchand P, Monteau F, Riu A, Andre F, Le Bizec B. 2009. Exposure assessment of French women and their newborn to brominated flame retardants: determination of tri- to deca- polybromodiphenylethers (PBDE) in maternal adipose tissue, serum, breast milk and cord serum. *Environ Pollut.* 157:164–173.
- Arbuckle TE, Kubwabo C, Walker M, Davis K, Lalonde K, Kosarac I, Wen SW, Arnold DL. 2013. Umbilical cord blood levels of perfluoroalkyl acids and polybrominated flame retardants. *Int J Hyg Environ Health.* 216:184–194.
- Bi X, Qu W, Sheng G, Zhang W, Mai B, Chen D, Yu L, Fu J. 2006. Polybrominated diphenyl ethers in South China maternal and fetal blood and breast milk. *Environ Pollut.* 144:1024–1030.
- Carrizo D, Grimalt JO, Ribas-Fito N, Sunyer J, Torrent M. 2007. Influence of breastfeeding in the accumulation of polybromodiphenyl ethers during the first years of child growth. *Environ Sci Technol.* 41:4907–4912.
- Chao HR, Wang SL, Lee WJ, Wang YF, Pöpke O. 2007. Levels of polybrominated diphenyl ethers (PBDEs) in breast milk from central Taiwan and their relation to infant birth outcome and maternal menstruation effects. *Environ Int.* 33:239–245.
- Chen A, Park JS, Linderholm L, Rhee A, Petreas M, DeFranco EA, Dietrich KN, Ho SM. 2013. Hydroxylated polybrominated diphenyl ethers in paired maternal and cord sera. *Environ Sci Technol.* 47:3902–3908.
- Chen ZJ, Liu HY, Cheng Z, Man YB, Zhang KS, Wei W, Du J, Wong MH, Wang HS. 2014. Polybrominated diphenyl ethers (PBDEs) in human samples of mother-newborn pairs in South China and their placental transfer characteristics. *Environ Int.* 73:77–84.
- Choi G, Kim S, Kim S, Choi Y, Kim HJ, Lee JJ, Kim SY, Lee S, Moon HB, Choi S. 2014. Occurrences of major polybrominated diphenyl ethers (PBDEs) in maternal and fetal cord blood sera in Korea. *Sci Total Environ.* 491–492:219–226.
- Costa LG, Giordano G. 2007. Developmental neurotoxicity of polybrominated diphenyl ether (PBDE) flame retardants. *Neurotoxicology.* 28:1047–1067.
- Costa LG, Giordano G, Tagliaferri S, Caglieri A. 2008. Polybrominated diphenyl ether (PBDE) flame retardants: environmental contamination, human body burden and potential adverse health effects. *Acta Biomed.* 79:172–183.
- Covaci A, de Boer J, Ryan JJ, Voorspoels S, Schepens P. 2002. Distribution of organobrominated and organochlorinated contaminants in Belgian human adipose tissue. *Environ Res.* 88:210–218.
- Covaci A, Voorspoels S, Roosens L, Jacobs W, Blust R, Neels H. 2008. Polybrominated diphenyl ethers (PBDEs) and polychlorinated biphenyls (PCBs) in human liver and adipose tissue samples from Belgium. *Chemosphere.* 73:170–175.
- Darnerud PO, Eriksen GS, Jóhannesson T, Larsen PB, Viluksela M. 2001. Polybrominated diphenyl ethers: occurrence, dietary exposure, and toxicology. *Environ Health Perspect.* 109(s1):49–68.
- Dingemans MM, de Groot A, van Kleef RG, Bergman Å, van den Berg M, Vijverberg HP, Westerink RH. 2008. Hydroxylation increases the neurotoxic potential of BDE-47 to affect exocytosis and calcium homeostasis in PC12 cells. *Environ Health Perspect.* 116:637–643.
- Domingo JL. 2012. Polybrominated diphenyl ethers in food and human dietary exposure: a review of the recent scientific literature. *Food Chem Toxicol.* 50:238–249.
- Eriksson P, Fredriksson A. 1996. Neonatal exposure to 2,2',5,5'-tetrachlorobiphenyl causes increased susceptibility in the cholinergic transmitter system at adult age. *Environ Toxicol Pharmacol.* 1:217–220.
- Eskenazi B, Chevrier J, Rauch SA, Kogut K, Harley KG, Johnson C, Trujillo C, Sjödin A, Bradman A. 2013. In utero and childhood polybrominated diphenyl ether (PBDE) exposures and neurodevelopment in the CHAMACOS study. *Environ Health Perspect.* 121:257–262.
- Foster WG, Gregorovich S, Morrison KM, Atkinson SA, Kubwabo C, Stewart B, Teo K. 2011. Human maternal and umbilical cord blood concentrations of polybrominated diphenyl ethers. *Chemosphere.* 84:1301–1309.
- Frederiksen M, Vorkamp K, Thomsen M, Knudsen LE. 2009. Human internal and external exposure to PBDEs – A review of levels and sources. *Int J Hyg Environ Health.* 212:109–134.
- Frederiksen M, Thomsen C, Frøshaug M, Vorkamp K, Thomsen M, Becher G, Knudsen LE. 2010. Polybrominated diphenyl ethers in paired samples of maternal and umbilical cord blood plasma and associations with house dust in a Danish cohort. *Int J Hyg Environ Health.* 213:233–242.
- Gómara B, Herrero L, Ramos JJ, Mateo JR, Fernandez MA, Garcia JF, Gonzalez MJ. 2007. Distribution of polybrominated diphenyl ethers in human umbilical cord serum, paternal serum, maternal serum, placentas, and breast milk from Madrid population. *Environ Sci & Technol.* 41:6961–6968.
- Guvenius DM, Aronsson A, Ekman-Ordeberg G, Bergman A, Norén K. 2003. Human prenatal and postnatal exposure to polybrominated diphenyl ethers, polychlorinated biphenyls, polychlorobiphenyls, and pentachlorophenol. *Environ Health Perspect.* 111:1235–1241.
- Herbstman JB, Sjödin A, Apelberg BJ, Witter FR, Patterson DG, Halden RU, Jones RS, Park A, Zhang Y, Heidler J, Needham LL. 2007. Determinants of prenatal exposure to polychlorinated biphenyls (pcbs) and polybrominated diphenyl ethers (PBDEs) in an urban population. *Environ Health Perspect.* 115:1794–1800.

- Herbstman JB, Sjödin A, Kurzon M, Lederman SA, Jones RS, Rauh V, Needham LL, Tang D, Niedzwiecki M, Wang RY, Perera F. 2010. Prenatal exposure to PBDEs and neurodevelopment. *Environ Health Perspect.* 118:712–719.
- Hites RA. 2004. Polybrominated diphenyl ethers in the environment and in people: a meta-analysis of concentrations. *Environ Sci Technol.* 38:945–956.
- Jakobsson K, Fång J, Athanasiadou M, Rignell-Hydbom A, Bergman Å. 2012. Polybrominated diphenyl ethers in maternal serum, umbilical cord serum, colostrum and mature breast milk. Insights from a pilot study and the literature. *Environ Int.* 47:121–130.
- Jaraczewska K, Lulek J, Covaci A, Voorspoels S, Kaluba-Skotarczak A, Drews K, Schepens P. 2006. Distribution of polychlorinated biphenyls, organochlorine pesticides and polybrominated diphenyl ethers in human umbilical cord serum, maternal serum and milk from Wielkopolska region. *Sci Total Environ.* 372:20–31.
- Kang CS, Lee JH, Kim SK, Lee KT, Lee JS, Park PS, Yun SH, Kannan K, Yoo YW, Ha JY, Lee SW. 2010. Polybrominated diphenyl ethers and synthetic musks in umbilical cord serum, maternal serum, and breast milk from Seoul. *South Korea Chemosphere.* 80:1116–122.
- Kawashiro Y, Fukata H, Omori-Inoue M, Kubonoya K, Jotaki T, TAKIGAM H, Sakai SI, Mori C. 2008. Perinatal exposure to brominated flame retardants and polychlorinated biphenyls in Japan. *Endocr J.* 55:1071–1084.
- Kim TH, Lee YJ, Lee E, Patra N, Lee J, Kwack SJ, Kim KB, Chung KK, Han SY, Han JY, Lee BM. 2009. Exposure assessment of polybrominated diphenyl ethers (PBDE) in umbilical cord blood of Korean infants. *J Toxicol and Environ Health A.* 72:1318–1326.
- Kim UJ, Lee IS, Kim HS, Oh JE. 2011. Monitoring of PBDEs concentration in umbilical cord blood and breast milk from Korean population and estimating the effects of various parameters on accumulation in humans. *Chemosphere.* 85:487–493.
- Kim TH, Bang Du Yeon, Lim HJ, Won AJ, Ahn MY, Patra N, Chung KK, Kwack SJ, Park KL, Han SY, Choi WS, Han JY. 2012. Comparisons of polybrominated diphenyl ethers levels in paired South Korean cord blood, maternal blood, and breast milk samples. *Chemosphere.* 87:97–104.
- Kuriyama SN, Talsness CE, Grote K, Chahoud I. 2005. Developmental exposure to low dose PBDE 99: effects on male fertility and neurobehavior in rat offspring. *Environ Health Perspect.* 113:149–154.
- Li LX, Chen L, Meng XZ, Chen BH, Chen SQ, Zhao Y, Zhao LF, Liang Y, Zhang YH. 2013. Exposure levels of environmental endocrine disruptors in mother-newborn pairs in China and their placental transfer characteristics. *PLoS One.* 8:e62526.
- Lin SM, Chen FA, Huang YF, Hsing LL, Chen LL, Wu LS, Liu TS, Chang-Chien GP, Chen KC, Chao HR. 2011. Negative associations between PBDE levels and thyroid hormones in cord blood. *Int J Hyg Environ Health.* 214:115–120.
- Linares V, Bellés Montserrat, Domingo JL. 2015. Human exposure to PBDE and critical evaluation of health hazards. *Arch Toxicol.* 89:335–356.
- Ma Y, Salamova A, Venier M, Hites RA. 2013. Has the phase-out of pbdes affected their atmospheric levels? trends of pbdes and their replacements in the Great Lakes atmosphere. *Environ Sci Technol.* 47:11457–11464.
- Mazdai A, Dodder NG, Abernathy MP, Hites RA, Bigsby RM. 2003. Polybrominated diphenyl ethers in maternal and fetal blood samples. *Environ Health Perspect.* 111:1249–1252.
- Meerts IA, Letcher RJ, Hoving S, Marsh G, Bergman A, Lemmen JG, van der Burg B, Brouwer A. 2001. In vitro estrogenicity of polybrominated diphenyl ethers, hydroxylated PDBEs, and polybrominated bisphenol A compounds. *Environ Health Perspect.* 109:399–407.
- Meijer L, Weiss J, van Velzen M, Brouwer A, Bergman AKE, Sauer PJ. 2008. Serum concentrations of neutral and phenolic organohalogenes in pregnant women and some of their infants in The Netherlands. *Environ Sci Technol.* 42:3428–3433.
- Pacyniak E, Roth M, Hagenbuch B, Guo GL. 2010. Mechanism of polybrominated diphenyl ether uptake into the liver: PBDE congeners are substrates of human hepatic OATP transporters. *Toxicol Sci.* 115:344–353.
- Petreas M, Nelson D, Brown FR, Goldberg D, Hurley S, Reynolds P. 2011. High concentrations of polybrominated diphenylethers (PBDEs) in breast adipose tissue of California women. *Environ Int.* 37:190–197.
- Roze E, Meijer L, Bakker A, Van Braeckel KN, Sauer PJ, Bos AF. 2009. Prenatal exposure to organohalogenes, including brominated flame retardants, influences motor, cognitive, and behavioral performance at school age. *Environ Health Perspect.* 117:1953–1958.
- Schechter A, Johnson-Welch S, Tung KC, Harris TR, Pöpke O, Rosen R. 2007. Polybrominated diphenyl ether (PBDE) levels in livers of U.S. human fetuses and newborns. *J Toxicol Environ Health A.* 70:1–6.
- Sjödin A, Patterson DG Jr, Bergman Åke. 2001. Brominated flame retardants in serum from U.S. blood donors. *Environ Sci Technol.* 35:3830–3833.
- Sjödin A, Jones RS, Focant JF, Lapeza C, Wang RY, McGahee EE 3rd, Zhang Y, Turner WE, Slazyk B, Needham LL, Patterson DG Jr. 2004. Retrospective time-trend study of polybrominated diphenyl ether and polybrominated and polychlorinated biphenyl levels in human serum from the United States. *Environ Health Perspect.* 112:654–658.
- Viberg H, Fredriksson A, Eriksson P. 2002. Neonatal exposure to the brominated flame retardant 2,2',4,4',5-pentabromodiphenyl ether causes altered susceptibility in the cholinergic transmitter system in the adult mouse. *Toxicol Sci.* 67:104–107.
- Vizcaino E, Grimalt JO, Lopez-Espinosa MJ, Llop S, Rebagliato M, Ballester F. 2011. Polybromodiphenyl ethers in mothers and their newborns from a non-occupationally exposed population (Valencia, Spain). *Environ Int.* 37:152–157.

- Vuong AM, Webster GM, Romano ME, Braun JM, Zoeller RT, Hoofnagle AN, Sjödin A, Yolton K, Lanphear BP, Chen A. **2015**. Maternal polybrominated diphenyl ether (PBDE) exposure and thyroid hormones in maternal and cord sera: the HOME study, Cincinnati, USA. *Environ Health Perspect.* 123:1079–1085.
- Weiss JML, Sauer P, Linderholm L, Athanassiadis J, Bergman A. **2004**. PBDE and HBCDD levels in blood from Dutch mothers and infants – Analysis of a Dutch Groningen Infant Cohort. *Organohalogen Compd.* 66:2647–2652.
- de Wit CA. **2002**. An overview of brominated flame retardants in the environment. *Chemosphere.* 46:583–624.
- Wu K, Xu X, Liu J, Guo Y, Li Y, Huo X. **2010**. Polybrominated diphenyl ethers in umbilical cord blood and relevant factors in neonates from Guiyu. *Environ Sci Technol.* 44:813–819.